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The  porcine  reproductive  and  respiratory  syndrome  virus  (PRRSV)  is  an  RNA  virus  that  causes  repro-
ductive  failure  in  sows  and  boars,  and  respiratory  disease  in  pigs  of  all ages.  Antibodies  against  several
viral  envelope  proteins  are  produced  upon  infection,  and  the  glycoproteins  GP4  and  GP5 are  known  tar-
gets  for  virus  neutralization.  Still,  substantial  evidence  points  to  the  presence  of  more,  yet unidentiﬁed
neutralizing  antibody  targets  in  the  PRRSV  envelope  proteins.  The  current  study  aimed  to  identify  and
characterize  linear  antigenic  regions  (ARs)  within  the  entire  set  of  envelope  proteins  of the  European
prototype  PRRSV  strain  Lelystad  virus  (LV).
Seventeen LV-speciﬁc  antisera  were  tested  in  pepscan  analysis  on GP2,  E,  GP3,  GP4,  GP5 and  M,  resulting
in  the  identiﬁcation  of  twenty-one  ARs  that  are  capable  of  inducing  antibodies  upon  infection  in  pigs.  A
considerable  number  of  these  ARs  correspond  to  previously  described  epitopes  in different  European-
and  North-American-type  PRRSV  strains.  Remarkably,  the  largest  number  of ARs  was found  in  GP3,  and
two  ARs  in the  GP3  ectodomain  consistently  induced  antibodies  in  a  majority  of  infected  pigs.  In  contrast,
all  remaining  ARs,  except  for a highly  immunogenic  epitope  in  GP4,  were  only  recognized  by  one  or  a
few  infected  animals.
Sensitivity to  antibody-mediated  neutralization  was  tested  for a  selected  number  of  ARs  by  in  vitro
virus-neutralization  tests  on  alveolar  macrophages  with  peptide-puriﬁed  antibodies.  In addition  to  the
known  neutralizing  epitope  in  GP4,  two  ARs  in  GP2  and  one  in  GP3  turned  out  to be  targets  for  virus-
neutralizing  antibodies.  No  virus-neutralizing  antibody  targets  were  found  in E,  GP5  or M.  Since  the
neutralizing  AR  in  GP3  induced  antibodies  in  a majority  of  infected  pigs,  the  immunogenicity  of  this
AR  was  studied  more  extensively,  and  it was  demonstrated  that the  corresponding  region  in  GP3  of
virus  strains  other  than  LV  also  induces  virus-neutralizing  antibodies.  This  study  provides  new  insights
into  PRRSV  antigenicity,  and  contributes  to the  knowledge  on protective  immunity  and  immune  evasion
strategies  of  the  virus.
. Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV)
as discovered during the late eighties as the cause of severe
eproductive failure in sows, and is considered today as one of the
ost important pathogens in the swine industry [1–3]. Infection
f sows can lead to late term abortion, early farrowing and the
irth of weak-born piglets, while infected boars show decreased
perm quality and virus excretion in the semen [4–6]. On the other
and, PRRSV is involved in the porcine respiratory disease complex,
ausing respiratory problems in combination with secondary viral
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and bacterial infections [7,8]. The virus shows a restricted in vivo
cell tropism for certain subsets of macrophages, with alveolar
macrophages being the main target cell [9]. PRRSV is an enveloped
positive single-stranded RNA virus of the family Arteriviridae and
order Nidovirales [10]. The virion consists of a nucleocapsid core
that is built up by nucleocapsid protein (encoded by open reading
frame 7, ORF7) in association with the viral RNA. The nucleocapsid is
surrounded by a lipid envelope in which six structural proteins are
embedded: the glycoproteins GP2 (ORF2a), GP3 (ORF3), GP4 (ORF4)
and GP5 (ORF5), and the non-glycosylated proteins M (ORF6) and
E (ORF2b). GP5 and M are considered to be the most abundant
proteins in the envelope, while the other envelope proteins are
present in lower amounts [11–14]. Similar to many other RNA
viruses, PRRSV shows a large genetic variability, which is amongst
Open access under CC BY-NC-ND license.other things reﬂected in variation in virulence, interaction with the
immune system and antigenic properties of viral proteins. Virus
strains are usually classiﬁed within a European (EU) and a North-
American (NA) genotype, based on ORF5 and/or ORF7 sequences,
cine 2
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lthough a high degree of variability exists within genotypes nowa-
ays [15–19].
Although PRRSV only emerged in the swine industry rather
ecently, the virus seems to have acquired a number of proper-
ies that allow escape from the host’s protective immunity. In
ddition to an imbalanced cytokine response, impaired cytotoxic
-cell activity and absence of antibody-dependent complement-
ediated cell lysis, the PRRSV-speciﬁc neutralizing antibody
esponse shows an aberrant course [20–22]. Virus-speciﬁc anti-
odies are produced after one or two weeks upon PRRSV infection.
owever, these antibodies are not able to reduce in vitro virus
eplication in primary porcine alveolar macrophages (PAM). Low
evels of virus-neutralizing antibodies appear not earlier than
hree to four weeks post infection, which is probably too late to
nﬂuence the acute phase of viremia [23–26]. Despite this weak
irus-neutralizing antibody response, it is known that the pres-
nce of sufﬁcient amounts of virus-neutralizing antibodies at the
nset of infection can offer certain protection against virus repli-
ation in the lungs, viremia and transplacental spread of the virus,
ndicating that PRRSV-speciﬁc antibodies can contribute to protec-
ive immunity [27,28]. The search for antigenic regions (ARs) that
re potential inducers of virus-neutralizing antibodies therefore
s a main topic of interest in PRRSV research. Antigenic charac-
erization of PRRSV by the use of mouse monoclonal antibodies
mAbs) has led to the discovery of neutralizing epitopes in GP4 of
U-type PRRSV and GP5 of both EU- and NA-type PRRSV strains,
nd it has been suggested that also M and GP3 can act as targets
or neutralizing mAbs [29–33]. Although mAbs can greatly con-
ribute to the identiﬁcation and characterization of ARs on viral
roteins, they cannot be used to evaluate the potential immuno-
enicity of these ARs in pigs. For this latter purpose, antibody
esponses against viral proteins and epitopes upon PRRSV infec-
ion have been evaluated in different studies, including studies
hat provide large maps of ARs [25,31,34–44]. Furthermore, some
orrelations between epitope-speciﬁc antibody responses and the
ppearance of virus-neutralizing antibodies have been described
31,35,41]. Still, the involvement of the different PRRSV proteins
nd epitopes in the induction of virus-neutralizing antibodies in
igs is not completely resolved, and substantial evidence points
o the presence of yet unidentiﬁed neutralizing antibody targets in
he PRRSV envelope proteins [30,44–48]. A more detailed antigenic
haracterization of the entire structural PRRSV proteome can cre-
te insights into the antiviral immune response, immune evasion
echanisms, the viral replication cycle and evolutionary proper-
ies of the virus, and it can play its part in the development of new
accines and diagnostic tools.
In a preceding study, the antibody response against ARs in GP4
pon PRRSV infection in pigs was studied, and the susceptibility of
ach AR to antibody-mediated neutralization was investigated by
he use of peptide-puriﬁed antibodies [49]. A similar approach was
sed in the current study to characterize ARs within all other enve-
ope proteins of the EU prototype PRRSV strain Lelystad virus (LV).
he speciﬁcity of the serum antibody response against ARs within E,
P2, GP3, GP4, GP5 and M was determined in LV-infected pigs. Next,
ntibodies against every separate AR were puriﬁed and their virus-
eutralizing capacity was determined. Finally, one AR in GP3 that
as target for virus-neutralizing antibodies and induced antibodies
n a majority of infected pigs was studied more extensively.
.  Materials and methods
.1.  Cell cultures and virusesPrimary  porcine alveolar macrophages (PAM) were obtained
rom four-week-old pigs from a PRRSV-negative herd as described
arlier [3]. The cells were cultivated in RPMI 1640, supplemented9 (2011) 4794– 4804 4795
with  10% fetal calf serum, 2 mM  l-glutamine, 1% non-essential
amino acids, 1 mM sodium pyruvate and a mixture of antibiotics
at 37 ◦C in a humidiﬁed atmosphere with 5% CO2. The EU proto-
type PRRSV strain LV and the EU-type PRRSV ﬁeld isolates 07V063
and 08V204 were used in this study. 07V063 was isolated from an
aborted fetus, derived from a Belgian farm during an outbreak of
PRRSV-associated reproductive disorders, while 08V204 was iso-
lated from a Belgian farm from the serum of eight-week-old healthy
piglets that showed PRRSV-speciﬁc antibodies. The viruses were
propagated in PAM, derived from either gnotobiotic piglets when
used for inoculation of animals or conventional piglets when used
in virus-neutralization tests (LV: 5th passage, 07V063: 2nd passage,
and 08V204: 3rd passage) [3,49]. ORF2–ORF6 sequences of the LV
stocks and ORF3 sequences of the 07V063 and 08V204 stocks were
determined as formerly described (primer sequences are available
upon request) [49]. GP3, GP4, GP5 and M amino acid (aa) sequences
of all LV stocks were identical to the sequences that are available in
GenBank (accession number M96262), and the same was true for
GP3 of 07V063 and 08V204 stocks (accession numbers GU737264
and GU737266). The GP2 sequences of both LV stocks were identi-
cal to the GenBank sequence, except for a conserved aa change in
the putative signal peptide at position 28 (proline to serine).
2.2.  Experimental inoculation of animals and collection of serum
and  broncho-alveolar lavage ﬂuid
All pigs used in this study were offspring of hybrid sows
(JSR Genepacker 90, English Landrace × Large White) and Piétrain
boars. The pigs were derived from a PRRSV-negative farm and the
seronegative status of the animals was conﬁrmed by IPMA [26]. At
14 weeks of age, the animals were intranasally inoculated with 106
TCID50 PRRSV. Eleven piglets (pigs A–K) were inoculated with the
PRRSV strain LV, blood was  drawn at 0, 7, 14, 20, 26 and 31 days
post inoculation (dpi), and sera were collected. Six more piglets
were inoculated with LV, of which sera were collected at either
52 dpi (pigs L–N) or 141 dpi (pigs O–Q) to maximize the chance
of identifying slowly developing antibody populations. The differ-
ent time points of end serum collection were randomly assigned to
the animals, without pre-selecting in any way. LV-inoculated pigs
A, B, E, I and K were euthanized at 45 dpi by intravenous injec-
tion of an overdose of Na-Pentobarbital 20% (Kela Laboratories)
after which serum was collected and lungs were isolated. Broncho-
alveolar lavage (BAL) ﬂuids were collected from the right lung by
ﬂushing with 120 mL  of PBS [50]. In addition to LV, 2 times six pigs
were inoculated with either PRRSV strain 07V063 (pigs 7A–7F) or
08V204 (8A–8F), and sera were collected at 45 dpi. Sera and BAL
ﬂuids were heat-inactivated (56 ◦C, 30 min) and stored at −70 ◦C
before use.
2.3.  Pepscan analysis and peptide ELISA
Pepscan analysis with porcine serum and peptide ELISA with
puriﬁed antibodies, porcine serum or BAL ﬂuid was  essentially
performed as described earlier [49]. Sets of overlapping dodecapep-
tides with an offset of 4 and an overlap of 8 aa were designed,
based on the complete sequences of GP2, E, GP3, GP4, GP5 and
M of LV, and the GP3 aa 49–76 region of 07V063 and 08V204.
Biotinylated peptides (BioTides) were chemically synthesized by
JPT Peptide Technologies, using the SPOT synthesis approach on
cellulose membranes. Synthesis was performed using a capping
step after each amino acid coupling to enable biotinylation of target
peptide only, which allows selective immobilization of correct pep-
tides in streptavidin-coated plates. A selected number of peptides
were applied to liquid chromatography–mass spectrometry anal-
ysis to substantiate proper technical synthesis performance and
identity. Streptavidin-coated 96-well plates (VWR International)
4 cine 2
w
w
i
o
p
s
a
S
a
w
t
w
p
w
e
a
(
w
r
p
a
u
e
t
O
t
p
t
E
s
2
f
[
c
(
t
N
i
t
s
c
t
W
a
e
i
m
a
2
f
p
w
0
n
t
a
i
a
w
respectively to avoid overlap between ARs. The selected ARs and796 M.  Vanhee et al. / Vac
ere coated with 0.1 g of BioTides in PBS with 0.5% Tween-20,
ashed, and blocked with 1% bovine serum albumin (R&D systems)
n 0.5% Tween-20. Test samples (porcine sera, puriﬁed antibodies
r BAL ﬂuids) were diluted in blocking buffer and incubated on the
eptide-coated plates. Sera were diluted 1/100 or used in two-fold
erial dilutions, BAL ﬂuids were used in two-fold serial dilutions,
nd puriﬁed antibodies were used in a concentration of 25 g/mL.
erum dilutions and antibody concentrations were chosen in such
 way that clear speciﬁc signals and minimal background signals
ere obtained, based on preliminary experiments. After incuba-
ion with the test samples, plates were washed and incubated
ith an optimal dilution of peroxidase-conjugated goat-anti-swine
olyclonal antibodies (Jackson ImmunoResearch), after which they
ere washed and developed with a substrate solution of tetram-
thylbenzidine and H2O2 (R&D systems). The reaction was stopped
fter 10 min  with 1 M H2SO4, and the optical density at 450 nm
OD450) was measured. All wash steps were performed with PBS
ith 0.5% Tween-20, and all incubation steps were carried out at
oom temperature for 1 h.
Serum or protein A-puriﬁed antibodies from a PRRSV-negative
ig were included as negative control for sera or peptide-puriﬁed
ntibodies, and PBS was used as control for BAL ﬂuids. OD450 val-
es obtained with test samples at a certain peptide were always
xpressed relative to the OD450 value obtained with the nega-
ive control sample at the same peptide (OD450 sample/negative,
D450 s/n). In pepscan analysis, the mean OD450 s/n over all pep-
ides within a protein was calculated. If the OD450 s/n at a certain
eptide was more than 2 times the mean over all peptides within
he same protein, the signal was considered speciﬁc. In peptide
LISA on a limited number of peptides, an OD450 s/n > 2 was  con-
idered a speciﬁc signal.
.4.  Puriﬁcation of peptide-speciﬁc serum antibodies
Puriﬁcation of peptide-speciﬁc serum antibodies was  per-
ormed by peptide afﬁnity chromatography as described before
49]. Sera with the highest amounts of antibodies of interest were
hosen to maximize puriﬁcation yields. 1 mg  of a 12-mer peptide
>80% purity, JPT Peptide Technologies) was covalently coupled
o a N-hydroxysuccinimide-activated sepharose column (HiTrap
HS-activated HP, GE Healthcare), following the manufacturer’s
nstructions. Heat-inactivated serum was clariﬁed by centrifuga-
ion, the pH was  adapted with 200 mM Na2HPO4 (pH 7.0), and the
erum was ﬁltrated over a 0.2 m ﬁlter. After equilibration of the
olumn with 20 mM Na2HPO4 (pH 7.0), serum was run over it and
he column was subsequently washed with 20 mM  Na2HPO4 buffer.
hen no more protein could be detected by spectrophotometry
t 278 nm in the wash fractions, peptide-speciﬁc antibodies were
luted from the column with 0.1 M glycine (pH 2.7) and collected
n 1 M Tris (pH 8.0). Elution fractions that contained protein, as
easured by spectrophotometry at 278 nm,  were pooled, dialyzed
gainst PBS and stored at −70 ◦C.
.5.  Single-replication virus-neutralization test on PAM
Single-replication virus-neutralization test on PAM was per-
ormed as described earlier [49]. Two-fold serial dilutions of
eptide-speciﬁc serum antibodies, sera or BAL ﬂuids were mixed
ith equal volumes of PAM-grown virus (either LV, 07V063 or
8V204) resulting in a ﬁnal titre of 105 TCID50/mL, and in case of
eutralization with puriﬁed antibodies, a ﬁnal antibody concen-
ration range of 400–13 g/mL. Protein A-puriﬁed antibodies from serologically PRRSV-negative pig, negative serum or PBS were
ncluded as mock condition in neutralization tests with puriﬁed
ntibodies, sera or BAL ﬂuids respectively. Virus-antibody mixtures
ere incubated for 1 h at 37 ◦C and transferred to a 96-well plate9 (2011) 4794– 4804
(100  L/well) with PAM (105 cells/well) that were cultivated dur-
ing 48 h prior to use. The inoculum was removed after 1 h and
replaced by medium, after which the cells were further incubated
for another 10 h, ﬁxed by drying, and stored at −20 ◦C. The cells
were stained for PRRSV infection with mAb  13E2 [51] against the
nucleocapsid protein of PRRSV and peroxidase conjugated goat-
anti-mouse polyclonal antibodies (Dako), followed by development
with 3-amino-9-ethylcarbazole. The number of infected cells in
each well was  counted in three ﬁelds at 200× magniﬁcation,
and expressed relative (%) to the mean number of infected cells
for all mock conditions within the same experiment. Neutraliza-
tion experiments with peptide-puriﬁed antibodies were performed
in four-fold. The relative % of infected cells was analyzed by 2-
way analysis of variance, followed by Bonferroni’s post-tests to
determine statistically signiﬁcant differences between treatment
and mock antibody conditions for a given antibody concentration.
P < 0.01 was  chosen as level of statistical signiﬁcance. Statistical
analysis was  performed using GraphPad Prism version 5.0a. Neu-
tralization experiments with sera and BAL ﬂuids were performed in
duplicate, and titres were determined as the reciprocal of the high-
est dilution that resulted in more than 50% reduction of infected
cells.
3. Results
3.1. Reactivity of LV antisera with linear peptides of all envelope
proteins
Seventeen PRRSV-negative piglets were inoculated with LV at
the age of six weeks, and all pigs showed viremia during two to four
weeks (data not shown). To determine the reactivity of serum with
linear dodecapeptides covering all envelope proteins upon infec-
tion with LV, a pepscan analysis was performed on GP2, E, GP3,
GP4, GP5 and M with a 1/100 dilution of sera that were collected
at 31 (n = 11), 52 (n = 3) or 141 (n = 3) dpi. Thirty-nine peptides in
total within GP2, GP3, GP4, GP5 and M were recognized by one or
more sera, while no peptides of the E protein were recognized by
any of the samples. Peptide reactivity patterns of individual ani-
mals are available as supplementary data. Reactive peptides were
grouped into antigenic regions (ARs) of 12–38 amino acids (aa)
based on reactivity of individual sera with successive overlapping
dodecapeptides (Table 1). Five ARs were deﬁned in GP2, eight in
GP3, one in GP4, four in GP5 and three in the M protein. Four
of these ARs are encoded by overlapping coding regions: GP2-V
(ORF2/ORF3) and GP3-VII, GP3-VIII and GP4-I (ORF3/ORF4). Thir-
teen ARs (GP2-IV, GP3-I, GP3-II, GP3-III, GP3-IV, GP3-V, GP3-VIII,
GP4-I, GP5-I, GP5-III, GP5-IV, M-I  and M-II) were recognized by
at least 2 sera and were selected for further study. The remain-
ing ARs, that only induced antibodies in one out of seventeen pigs
were not included in further experiments, since it is questionable
whether these can be considered relevant ARs or epitopes. AR GP2-
II was only recognized by serum of one pig, collected at 141 dpi,
but because of the interesting position of this region in the N-
terminal end of the putative ectodomain of the GP2 protein, this
region was exceptionally also selected for further analysis [52].
Within the selected ARs, a core of 12 aa was deﬁned by the pep-
tide that showed reactivity with the highest number of sera, or
in case of an equal number of reactive sera, by the peptide that
gave the strongest signals in pepscan. As an exception, the cores
of ARs GP3-III and GP3-IV were deﬁned as peptides 22 and 25their core peptides are indicated in bold in Table 1. The AR that
was found in GP4 has already been extensively studied for EU-
type PRRSV, and was included in the current study as gold standard
[29,33,40,49,53–55].
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Table 1
Antigenic regions in GP2, GP3, GP4, GP5 and M of LV. Seventeen six-weeks old piglets were intranasally inoculated with LV, serum was collected at 31, 52 or 141 dpi and
serum reactivity with linear dodecapeptides in the envelope proteins GP2, GP3, GP4, GP5 and M was  tested in pepscan analysis. Reactive peptides were grouped into antigenic
regions (ARs), based on reactivity of individual animals with successive overlapping dodecapeptides. For each AR, the number of reactive pigs out of 17 is given, together
with the numbering, amino acid sequence and positioning of the peptides that deﬁne the AR. References are given for ARs that have earlier been identiﬁed by the use of mAbs
(in  italics) or porcine antisera, in either EU- or NA-type viruses (*non-neutralizing epitope; **neutralizing epitope). ARs that were recognized by at least 2 pigs as well as AR
GP2-II  were selected for further study. Core sequences (bold) within these ARs were deﬁned, based on the number of reactive pigs with every peptide and with avoidance of
overlap.
Protein AR #Reactive pigs (out of 17) Peptide Amino acid sequence (position) Previously described (in EU- or
NA-type virus)
GP2 GP2-I 1 1 MQWGHCGVKSAS (1–12)
GP2-II 1 9 PYCLGSPSQDGY (33–44) Oleksiewicz et al. [38] (EU)
10  GSPSQDGYWSFF (37–48) de Lima et al. [44] (NA)
GP2-III  1 23 KHPLGMFWHMRV (89–100)
GP2-IV 2 30 EHSGQAAWKQVV (117–128) Oleksiewicz et al. [38] (EU)
de  Lima et al. [44] (NA)
GP2-V 1 51 FRQWLISVHASI (201–212)
GP3 GP3-I 13 14 ICMPCSTSQAAR (53–64) Oleksiewicz et al. [40] (EU)
15  CSTSQAARQRLE (57–68) Oleksiewicz et al. [38] (EU)
16 QAARQRLEPGRN (61–72) de Lima et al. [44] (NA)
Zhou  et al. [42] (NA)
GP3-II 12 18 PGRNMWCKIGHD (69–80) Oleksiewicz et al. [40] (EU)
19  MWCKIGHDRCEE (73–84) Oleksiewicz et al. [38] (EU)
20  IGHDRCEERDHD (77–88) Van Breedam et al. [51] (EU)*
21  RCEERDHDELLM (81–92) de Lima et al. [44] (NA)
Zhou  et al. [42] (NA)
GP3-III 2 22 RDHDELLMSIPS (85–96) de Lima et al. [44] (NA)
23  ELLMSIPSGYDN (89–100) Zhou et al. [42] (NA)
GP3-IV 2 24 SIPSGYDNLKLE (93–104) de Lima et al. [44] (NA)
25  GYDNLKLEGYYA (97–108) Zhou et al. [42] (NA)
GP3-V  5 27 GYYAWLAFLSFS (105–116) Zhou et al. [42] (NA)
GP3-VI 1 36 QFICAEHDGHNS (141–152)
GP3-VII 1 46 EWLRPLFSSWLV (181–192)
GP3-VIII 2 62 KFPSESRPNVVK (245–256) Oleksiewicz et al. [39] (EU)
63  ESRPNVVKPSVL (249–260)
GP4 GP4-I 17 13 DINCFRPHGVSA (49–60) Meulenberg et al. [29] (EU)**
14  FRPHGVSAAQEK (53–64) Oleksiewicz et al. [40] (EU)
15  GVSAAQEKISFG (57–68) Costers et al. [33] (EU)**
16 AQEKISFGKSSQ (61–72) Vanhee et al. [49] (EU)**
17  ISFGKSSQCREA (65–76) de Lima et al. [44] (NA)
GP5 GP5-I 3 9 DGNGDSSTYQYI (33–44) Van Breedam et al. [51] (EU)*
10 DSSTYQYIYNLT (37–48) Ostrowski et al. [31] (NA)**
11  YQYIYNLTICEL (41–52) Plagemann et al. [41] (NA)**
de  Lima et al. [44] (NA)
GP5-II 1 37 NFIVDDRGRVHR (145–156) Rodriguez et al. [56] (EU)*
GP5-III  5 41 IVVEKLGKAEVD (161–172) Rodriguez et al. [56] (EU)*
42  KLGKAEVDGNLV (165–176) Zhou et al. [57] (NA)
43  AEVDGNLVTIKH (169–180)
GP5-IV 2 48 QPLTRTSAEQWEA (189–201) Oleksiewicz et al. [38] (EU)
Rodriguez  et al. [56] (EU)*
de  Lima et al. [44] (NA)
Zhou  et al. [57] (NA)
M M-I 2 1 MGGLDDFCNDPI (1–12)
M-II 2 32 SASGNRAYAVRK (125–136) Oleksiewicz et al. [38] (EU)
33  NRAYAVRKPGLT (129–140)
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.2. Virus neutralization by peptide-speciﬁc serum antibodies
Peptide-speciﬁc antibodies against the core peptide of each sep-
rate AR were puriﬁed from polyclonal sera by peptide afﬁnity
hromatography. All puriﬁcations yielded positive protein frac-
ions as measured by spectrophotometry at 278 nm,  except for
uriﬁcation against peptide GP3.27, which was further omitted
rom this study. Peptide-puriﬁed antibody fractions were tested
t a concentration of 25 g/mL in peptide ELISA on the respective
omologous and heterologous peptides to determine their speci-
city. All antibodies recognized the corresponding homologous
eptide, although the ELISA signal obtained with the M.1-speciﬁc
ntibody fraction was clearly lower compared to that of the other
ntibody fractions, and also the GP2.30-speciﬁc antibodies showed
ome lower reactivity (Fig. 1). None of the antibodies clearly reactedLVLGGKRAVKRG (153–164) Oleksiewicz et al. [38] (EU)
de  Lima et al. [44] (NA)
with  any of the respective heterologous peptides, further conﬁrm-
ing their speciﬁcity, although antibodies against peptide GP3.62
showed rather high reactivity with heterologous peptides.
Peptide-puriﬁed antibodies were used in single-replication
virus-neutralization tests on PAM to determine the effect of anti-
bodies, speciﬁc to each AR on in vitro virus replication. Serum
antibodies against peptide GP4.15 were able to reduce viral repli-
cation in PAM in a dose-dependent manner in a similar way as
previously described (Fig. 2, gray lines) [49]. Antibodies against
peptide GP2.10, GP2.30, GP3.16 and GP3.62 were also able to reduce
viral replication in PAM in a concentration-dependent manner
(Fig. 2, black lines). A signiﬁcant reduction in viral replication was
observed with antibody concentrations starting from 100 g/mL
for antibodies against GP2.10, GP2.30 and GP3.62, while GP3.16-
speciﬁc antibodies already exerted a signiﬁcant effect at 50 g/mL
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Fig. 1. Reactivity of peptide-puriﬁed antibodies with homologous and heterologous peptides in ELISA. Peptide-puriﬁed antibodies against core peptides of ARs in LV were
tested  in a concentration of 25 g/mL in ELISA on the respective homologous (black bars) and heterologous (white bars) peptides. OD450 values obtained with test samples
(s)  were expressed relative to the OD450 value obtained with protein A-puriﬁed antibodies from a PRRSV-negative pig (n) at the same peptide (OD450 s/n). Groups of bars
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Belgian PRRSV ﬁeld isolates, 07V063 and 08V204, were selected.
These viruses respectively show 89.0% and 84.5% GP3 aa homology
with LV, and are 81.5% homologous to each other. The aa sequences
Table 2
Neutralizing antibody titres and ELISA titres against antigenic regions GP3-I and
GP4-I in sera and BAL ﬂuids of LV-infected pigs at 45 dpi. Sera and BAL ﬂuids of pigs
A, B, E, I and K were collected at 45 days post inoculation with LV. Virus-neutralizing
antibody  titres (log2) were determined by single-replication virus-neutralization
test  on PAM. Serum and BAL ﬂuid reactivity with peptides 14, 15 and 16 of both
GP3  and GP4 was quantiﬁed by peptide ELISA with ten-fold serial dilutions (s) of
serum or BAL ﬂuid. Serial dilutions of a negative (n) serum or BAL ﬂuid sample were
included, and titres (log2) were determined as the reciprocal of the highest dilution
for which an OD450 s/n of 2 or more was observed.
Pig Sample Neutralization
titre (log2)
Peptide  ELISA titre (log2)
GP3 GP4
14 15 16 14 15 16
A Serum 5.0 <3.3 6.6 10.0 10.0 10.0 13.3
BAL  1.6 <3.3 <3.3 3.3 3.3 3.3 6.6
B Serum 7.0 <3.3 10.0 6.6 10.0 10.0 10.0
BAL 4.6  <3.3 3.3 3.3 3.3 3.3 3.3
E Serum 3.0 <3.3 10.0 10.0 6.6 10.0 10.0
BAL  <1.0 3.3 3.3 3.3 3.3 3.3 3.3epresent reactivity of single peptide-puriﬁed antibody fractions with peptides GP2
nd  M.33 (from left to right).
P < 0.01). Antibodies against all other peptides did not inﬂuence
iral replication in PAM in any concentration tested (Fig. 2, black
ines). Peptide-speciﬁc antibodies that did reduce viral replication
ever inﬂuenced viral infectivity as much as GP4-speciﬁc antibod-
es, although antibodies against peptide GP2.30 and GP3.62 were
ot tested in the highest concentration because of a low puriﬁcation
ield.
.3. Antibodies against AR GP3-I in serum and BAL ﬂuid upon
nfection  with LV
Of  the four newly identiﬁed ARs that are target for neutral-
zing antibodies, only GP3-I induced antibodies in a majority of
V-infected pigs (Table 1). The antibody response against this AR
pon infection was further evaluated and compared with the anti-
ody response against the well-characterized AR GP4-I [49]. Sera
f 11 LV-infected pigs (A–K), collected at 0, 7, 14, 20, 26 and 31 dpi,
ere tested in a 1/100 dilution in ELISA with peptides GP3.14,
P3.15 and GP3.16 within AR GP3-I, and peptides GP4.14, GP4.15
nd GP4.16 within AR GP4-I. OD450 s/n values of 2 or more were
onsidered positive, and the number of positive pigs per time point
s given for each peptide in Fig. 3. The earliest antibody response
gainst AR GP3-I (full lines) was observed at 14 dpi in one pig, while
0/11 animals showed reactivity with one or more peptides of this
R at 26 dpi. Antibodies against peptide GP3.16 were detected ear-
ier and in more animals than antibodies against peptides GP3.14
nd GP3.15, sustaining the choice of peptide 16 as core of AR GP3-I.
ntibodies against AR GP4-I (dashed lines) were detected in one
ig at 7 dpi, in more than half of the pigs at 14 dpi and in all animals
t 20 dpi, with peptide GP4.16 as main target within this AR.
BAL ﬂuids were collected from lungs of pigs A, B, E, I and K at
5 dpi, and virus-neutralizing antibody titres were determined by
ingle-replication virus-neutralization test on PAM. Antibody titres
n BAL ﬂuids were compared with titres in the serum at the same
ime point (Table 2). Virus-neutralizing antibodies were detected
n BAL ﬂuids from all but one animal, and these titres were lower
han in sera. Next, antibody titres against peptides 14, 15 and 16 of
oth GP3 and GP4 were determined with ten-fold serial dilutions
f sera and BAL ﬂuids in ELISA. All sera and BAL ﬂuids contained2.30, GP3.16, GP3.19, GP3.22, GP3.25, GP3.62, GP4.15, GP5.10, GP5.42, GP5.48, M.1
antibodies against both ARs, and antibody titres against AR GP4-
I were always equal or higher than GP3-I-speciﬁc antibody titres.
Also here, antibody titres were higher in sera than in BAL ﬂuids.
3.4.  Investigation of AR GP3-I in PRRSV ﬁeld isolates 07V063 and
08V204
It  was shown so far that AR GP3-I of LV induces antibodies in a
majority of infected pigs on the one hand, and that this AR is target
for virus-neutralizing antibodies on the other hand. To investigate
whether this is true for EU-type PRRSV strains other than LV, twoI Serum 4.6 3.3 10.0 10.0 13.3 13.3 13.3
BAL  1.0 <3.3 3.3 3.3 3.3 3.3 6.6
K Serum 4.0 <3.3 10.0 10.0 13.3 13.3 10.0
BAL 1.0  <3.3 <3.3 3.3 6.6 3.3 6.6
M. Vanhee et al. / Vaccine 29 (2011) 4794– 4804 4799
Fig. 2. Reduction of LV replication in PAM by peptide-speciﬁc antibodies. Afﬁnity-puriﬁed serum antibodies against peptides GP2.10, GP2.30, GP3.16, GP3.19, GP3.22,
GP3.25, GP3.62, GP5.10, GP5.42, GP5.48, M.1  and M.33 of LV were used in single-replication virus-neutralization tests on PAM. Two-fold serial dilutions of antibodies were
pre-incubated with LV (ﬁnal titre 105 TCID50/mL) and incubated on PAM. Antibody concentrations ranged between 13 g/mL and 200 or 400 g/mL, depending on the
puriﬁcation yield. Cells were ﬁxed after 11 h and infected cells were stained, quantiﬁed and expressed relative (%) to the mean number of infected cells in the presence of
mock  antibodies. The mean relative % infected cells of four experiments is given together with the standard error of the mean for each antibody concentration. Black symbols
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wepresent treatment antibody conditions, open symbols represent mock antibody
tatistically signiﬁcant differences (P < 0.01) between treatment and mock conditio
f AR GP3-I are given for LV, 07V063 and 08V204 in Fig. 4 (GenBank
96262.2, GU737264.1 and GU737266.1).
.4.1. Reactivity of 07V063 and 08V204 antisera with peptides in
R GP3-I
Six antisera against either 07V063 (pigs 7A–7F) or 08V204
pigs 8A–8F), collected at 45 dpi, were used in a 1/100 dilution in
LISA on peptides 13–17 of GP3 of the respective homologous virus
Table 3). Sera of LV-infected pigs A, B, E, I and K, collected at 45 dpi,
ere also included. All ﬁve LV antisera recognized both GP3 pep-
ides 15 and 16 of the homologous virus, while peptide 14 was not
ecognized. Sera of 5/6 07V063-inoculated pigs showed reactivity
ith peptide 15 of 07V063 GP3, and one of these sera also showeditions, and gray symbols represent neutralization by GP4.15-speciﬁc antibodies.
 indicated by asterisks.
reactivity  with peptide 16. The remaining 07V063 antiserum did
not react with any of the peptides within AR GP3-I of the homol-
ogous virus. All 08V204 antisera reacted with peptide 15 of the
08V204 AR GP3-I. Three of these sera showed additional reactivity
with peptide 14, one with peptide 16, and the two  remaining sera
with both peptides 14 and 16. None of the LV, 07V063 or 08V204
antisera showed reactivity with peptide 13 or 17, ﬂanking the AR
(not shown). From this, it was clear that all three virus strains
induced antibodies against peptides in AR GP3-I. However, in con-
trast to LV in which peptide 16 was considered the core of AR GP3-I,
peptide 15 was  considered the core of AR GP3-I of both 07V063 and
08V204, since this peptide was recognized by the highest number of
animals.
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Fig. 3. Serum reactivity of LV-infected pigs with antigenic regions GP3-I and GP4-I
at different time points post inoculation. Sera of 11 LV-infected pigs, collected at
different time points post inoculation, were tested in peptide ELISA on peptides 14,
15 and 16 of either GP3 or GP4. OD450 values obtained with test samples were
considered  to be speciﬁc when they exceeded 2 times the OD450 value obtained
with  mock serum at the same peptide. The number of reactive pigs at each time
point is given for the different peptides of the AR (full lines: GP3-I, dashed lines:
GP4-I).
Fig. 4. Amino acid sequence alignment of antigenic region GP3-I of LV, 07V063
and  08V204. GP3 amino acids 49–76 of LV, 07V063 and 08V204 are given, and the
positions of peptides 13–17 are indicated. Dots represent identical residues, the box
indicates AR GP3-I, and the gray sequences indicate the core peptides (LV: peptide
16,  07V063 and 08V204: peptide 15) of the AR for each virus.
Table  3
Reactivity of LV, 07V063 and 08V204 antisera with antigenic region GP3-I of homol-
ogous virus. Antisera against LV (pigs A, B, E, I and K), 07V063 (pigs 7A–7F) and
08V204  (pigs 8A–8F) were tested in peptide ELISA on GP3 peptides 14, 15 and 16 of
homologous viruses. Sera were diluted 1/100 and OD450 values were determined
at  each peptide for test samples (s) and a negative control serum (n). Signals were
considered positive when the OD450 s/n ratio was  2 or more.
Inoculum Pig GP3 peptides of homologous virus, recognized
by serum in peptide ELISA (OD450 s/n > 2)
14 15 16
LV A − + +
B  − + +
E −  + +
I  − + +
K  − + +
07V063 7A  − + −
7B  − + −
7C  − − −
7D −  + +
7E  − + −
7F  − + −
08V204 8A  + + −
8B  + + −
8C  + + +
8D  + + −
8E −  + +
8F  + + +9 (2011) 4794– 4804
3.4.2. Virus neutralization by peptide-speciﬁc serum antibodies
against  AR GP3-I of 07V063 and 08V204
Antibodies against peptide GP3.15 of 07V063 (CLTSQAASQRLE)
or 08V204 (CLTSQAAKQRLE) were puriﬁed from corresponding
polyclonal sera, and the speciﬁcity of puriﬁed antibody fractions
was conﬁrmed by peptide ELISA. Subsequently, the antibodies were
used in single-replication virus-neutralization tests on PAM with
homologous virus. Antibodies against peptide 15 in GP4 of 07V063
and 08V204 were previously described to neutralize homologous
virus, and were included here as a positive control for virus neu-
tralization (Fig. 5, gray lines) [49]. Similar to neutralization of LV
by antibodies against GP3.16 (Fig. 3), antibodies against GP3.15 of
07V063 and 08V204 reduced replication of the respective homolo-
gous virus strain in a dose-dependent manner (Fig. 5, black lines).
A clear and signiﬁcant reduction in viral replication was  observed
with antibody concentrations starting from 50 g/mL for both virus
strains.
4. Discussion
The speciﬁcity of the antibody response upon PRRSV infec-
tion has been studied frequently in the past, at the level of either
proteins, antigenic regions (ARs) or linear epitopes. Some studies
covered most or all envelope proteins, while others focused on a
limited selection of viral proteins. In the current study, the antibody
response against linear ARs within the entire set of envelope pro-
teins was  investigated in pigs upon infection with the EU prototype
PRRSV strain LV. Twenty-one ARs in total were recognized by serum
of one or more pigs, either at 31, 52 or at 141 dpi. A majority of these
ARs were recognized by sera collected at 31 dpi, indicating that the
antibody repertoire against linear ARs at that time point was largely
representative for the repertoire at later time points post infection.
Remarkably, a considerable number of ARs was recognized by no
more than one pig, and it is questionable whether these sequences
can be considered relevant ARs or epitopes. From the remaining
ARs, only GP4-I was  recognized by sera of all animals. This AR was
described earlier as a hypervariable region that strongly induces
antibodies in pigs, at least for different EU-type PRRSV strains
[40,49]. Furthermore, ARs GP3-I and GP3-II were recognized by a
majority of the animals, while the remaining ARs in GP3 and all ARs
in GP2, GP5 and M were recognized by not more than ﬁve out of
seventeen animals. These results match to a large extent with the
ﬁndings of Oleksiewicz et al. [38] that showed a high reactivity of
EU-type PRRSV antisera with ‘epitope sites’ corresponding to ARs
GP4-I, GP3-I and GP3-II [38]. NA-type PRRSV strains also induce
antibodies against these three ARs, but in a study of de Lima et al.
[44] AR GP4-I did not seem to be immunodominant, and ARs other
than GP3-I, GP3-II and GP4-I showed equal or higher immunogenic-
ity [42,44]. In addition to ARs GP3-I, GP3-II and GP4-I, a high number
of the remaining ARs within LV also correspond to earlier described
epitopes in other virus isolates of both the EU and NA genotypes. It
is known that regions corresponding to ARs GP2-II, GP2-IV, GP5-III,
GP5-IV and M-III of both EU- and NA-type PRRSV are able to induce
antibodies in pigs, while ARs GP3-VIII and M-II were described
earlier to induce antibodies for EU-type PRRSV, and GP3-III, GP3-
IV, GP3-V and GP5-I for NA-type viruses [31,38,39,41,42,44,56,57].
Despite  the high genetic variability of PRRSV, the antigenicity of
the viral proteins seems relatively well conserved, even at highly
variable sites. The antigenicity of certain regions in the envelope
proteins is probably more dependent on conserved structural char-
acteristics of the protein than on the exact aa sequence of the partic-
ular AR. This was  suggested earlier for GP4-I, but now seems to suit
for other ARs as well [49]. Remarkably, a large number of ARs identi-
ﬁed in this study are situated in GP3. The GP3 ectodomain contains
a considerable number of highly conserved cysteine residues and
N-glycosylation sites, indicating that this protein shows a strictly
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Fig. 5. Reduction of 07V063 or 08V204 replication in PAM by antibodies against peptide GP3.15 of the corresponding virus. Afﬁnity-puriﬁed serum antibodies against peptide
GP3.15  of either 07V063 or 08V204 were used in single-replication virus-neutralization tests on PAM with the respective homologous virus. Two-fold serial dilutions of
antibodies were mixed with virus (ﬁnal titre 105 TCID50/mL) and incubated on PAM. Antibody concentrations ranged between 13 g/mL and 400 g/mL. Cells were ﬁxed
after 11 h and infected cells were stained, quantiﬁed and expressed relative (%) to the mean number of infected cells in the presence of mock antibodies. The mean relative
%  infected cells of four experiments is given together with the standard error of the mean for each antibody concentration. Black symbols represent treatment antibody
conditions, open symbols represent mock antibody conditions, and gray symbols represent neutralization by antibodies against peptide GP4.15 of the corresponding virus
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vtrain.  Statistically signiﬁcant differences (P < 0.01) between treatment and mock co
rdered conformation that is conserved amongst PRRSV strains.
ithin the highly organized GP3 ectodomain, a large hydrophilic
egion is present that is not occupied by glycans. Interestingly, this
articular region turned out to determine a long antigenic stretch
hat can be subdivided into ﬁve distinct linear ARs (GP3-I to GP3-V),
omprising the more immunogenic ARs GP3-I and GP3-II.
For  all ARs that were recognized by sera of two animals or
ore, as well as for AR GP2-II, it was determined whether anti-
odies against the core peptide were able to inﬂuence in vitro
irus replication in PAM. Antibodies speciﬁc for peptides GP2.10
AR GP2-II), GP2.30 (GP2-IV), GP3.16 (GP3-I), GP3.62 (GP3-VIII) and
P4.15 (GP4-I) reduced in vitro virus replication in PAM in a dose-
ependent manner, while none of the other antibodies inﬂuenced
irus replication in any concentration tested. Although the anti-
ody response against GP2 was poorly studied in the past, the ARs
P2-II and GP2-IV have already been described for both EU- and
A-type PRRSV [38,44]. However, GP2 was never associated with
irus neutralization, and the identiﬁcation of two  neutralizing epi-
opes in this protein shows the value of studying the antigenicity of
he ‘minor’ PRRSV envelope proteins. Antibodies against ARs GP2-II
nd GP2-IV were only found in sera of 1 and 2 animals respectively,
nd for the former only at 141 dpi, indicating that the neutralizing
ntibody response against these ARs upon infection is probably of
inor importance. Further investigation is needed to determine
hether these ARs can be made more immunogenic in view of
nduction of GP2-speciﬁc neutralizing antibodies. AR GP3-I showed
imilar sensitivity to antibody-mediated neutralization as the ARs
n GP2. However, it is clear from this and other studies that a major-
ty of PRRSV-infected pigs develop antibodies against this AR, albeit
ather late post infection [38,42,44]. GP3 has been associated with
irus neutralization in the past, and it has been speculated that an
epitope site’ covering ARs GP3-I and GP3-II is involved in functional
nteractions with the host cell, suggesting that antibodies against
his site might have some neutralizing capacity [30,38]. However,
his is the ﬁrst study that offers direct evidence that antibodies
gainst AR GP3-I reduce viral infectivity in vitro, and thus have
he potential to contribute to protection in vivo. AR GP3-I is sit-
ated immediately upstream of GP3-II, and both ARs show similar
mmunogenicity. It is however clear from reactivity of individual
igs with peptides of either GP3-I or GP3-II that these are distinct
Rs, which was suggested earlier in other studies [38,42,44]. Anti-
odies against peptide GP3.19 within AR GP3-II did not inﬂuence
iral infectivity in vitro, in accordance to a study of Van Breedamns are indicated by asterisks.
et  al. [51] in which mAbs against this peptide did not reduce viral
replication in PAM [51].
In  addition to GP3-I, AR GP3-VIII in the C-terminal end of the
protein also showed some susceptibility to antibody-mediated
virus neutralization. This AR is however situated in the putative
endodomain of GP3 and should thus not be accessible for antibod-
ies [52]. One possible explanation for this apparent contradiction is
that the antibody fraction obtained by puriﬁcation against peptide
GP3.62 was not sufﬁciently pure. This antibody fraction showed
remarkably high reactivity with other peptides, and it cannot be
ruled out that remnant antibodies against other ARs, for example
strongly neutralizing GP4-speciﬁc antibodies, were responsible for
the observed neutralizing effect. Unfortunately, a lack of appro-
priate sera and weak puriﬁcation yields did not allow further
investigation of this issue. Another possibility however is that,
contradicting with topology prediction models, this part of GP3 is
indeed exposed at the virion surface, and in that case the AR would
be accessible for neutralizing antibodies. In any case, a neutralizing
antibody response against AR GP3-VIII would not be expected to
be of major signiﬁcance, since it seems that this AR in LV is not
at all highly immunogenic. Interestingly, Oleksiewicz et al. [39]
have shown that the corresponding region in a Danish EU-type iso-
late shows high immunogenicity in pigs on the one hand, but that
viruses with deletions in this region easily survive in the population
on the other hand [39]. While the predicted GP3 ectodomain seems
antigenically well conserved, the antigenicity of the C-terminal
endodomain is clearly more strain-dependent. This is sustained by
the fact that all ARs in the ectodomain of GP3  identiﬁed here are
also present in NA-type PRRSV, while this is not the case for AR
GP3-VIII [42,44].
Compared to the neutralizing capacity of GP4-speciﬁc antibod-
ies, antibodies against ARs GP2-II, GP2-IV, GP3-I and GP3-VIII were
clearly less potent to reduce viral infectivity in vitro. The differ-
ence in neutralizing capacity of antibodies against different ARs at
a similar concentration can be explained in two ways. On the one
hand, different ARs can show different susceptibilities to antibody-
mediated neutralization, inherent to the position and/or function
of this AR in the virion. This would then mean that even high con-
centrations of antibodies with maximal afﬁnity for the AR would
never be able to exert a strong neutralizing effect. On the other
hand, the peptide-puriﬁed antibodies used in this study may  have
a suboptimal afﬁnity and consequently show limited neutralizing
capacity. It is well possible that B-cell populations speciﬁc for cer-
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ain ARs have not undergone optimal afﬁnity maturation yet upon
ingle infection at the time points of serum collection. Further-
ore, a core of 12 aa was deﬁned for an entire AR, while it cannot
e ruled out that certain linear ARs are part of broader discontin-
ous or conformation-dependent epitopes. Whether there exists
ny potential to obtain stronger neutralizing antibodies against GP2
r GP3 is subject for further research, but it is clear from the cur-
ent study that ARs GP2-II, GP2-IV, GP3-I and GP3-VIII are at least
artially susceptible to antibody-mediated virus neutralization.
In  contrast to GP2, GP3 and GP4, none of the ARs in GP5 and
 were susceptible to antibody-mediated virus neutralization,
lthough it should be mentioned that puriﬁed antibodies against
R M-I  showed only low afﬁnity for the corresponding peptide in
LISA. It was not unexpected that ARs GP5-III and GP5-IV were
ot susceptible to neutralization, since these ARs are situated in
he predicted endodomain of the protein, and since it is known
hat mAbs against the corresponding regions in both EU- and
A-type viruses are not neutralizing [52,56,57]. The lack in neu-
ralization that was observed with antibodies against AR GP5-I is
owever more controversial. The corresponding region in NA-type
P5 was described earlier as the “primary neutralizing epitope” of
RRSV, and GP5 is generally considered the main target for virus-
eutralizing antibodies [41]. Several GP5-speciﬁc mAbs exist that
re able to reduce viral infectivity of NA-type PRRSV strains, and
ne of these is directed against AR GP5-I [31,58,59]. Furthermore,
orrelations between serum antibody responses against AR GP5-I of
A-type viruses and seroneutralization titres have been described
31,41]. While it is clear that antibodies against GP5-I can be formed
pon infection with NA-type PRRSV, de Lima et al. [44] however
howed that the immunogenicity of this AR is not exceptionally
igh [44]. For EU-type PRRSV, a neutralizing epitope has also been
dentiﬁed in GP5, but it is crucial to emphasize that this epitope is
ot the same as the one that is described for NA-type PRRSV, and
hat it does not correspond at all to AR GP5-I [31,32]. The neutraliz-
ng epitope in EU-type GP5 is located upstream of AR GP5-I, and is
n fact only susceptible to antibody-mediated neutralization in the
ontext of an in vitro selected virus phenotype that has never been
bserved in vivo [32]. No other neutralizing epitopes have been
escribed in GP5 of EU-type PRRSV to date. Furthermore, it was
ecently described that mAbs directed against AR GP5-I of LV are
ot able to inﬂuence virus infectivity in PAM, even at high concen-
rations [51]. This is in line with the results from the present study,
nd sustains the idea that although antibodies against AR GP5-I in
A-type PRRSV may  be able to reduce viral infectivity, this is not the
ase for LV and possibly neither for other EU-type viruses. This dis-
repancy can currently not be explained, but it is very well possible
hat the structural properties of the GP5 protein vary amongst virus
trains, leading to different antigenic properties of this protein.
Since  ARs GP3-I and GP4-I were both immunogenic and target
or neutralizing antibodies, the serum antibody response against
hese ARs was further studied. While antibodies against GP4-I
ppeared relatively fast upon infection in a majority of the ani-
als, it clearly lasted longer for most animals to develop antibodies
gainst AR GP3-I. Moreover, antibody titres in end sera and BAL
uids against GP3-I were invariably lower than against GP4-I.
lthough most pigs are able to develop antibodies against both ARs,
P4-I clearly shows the highest immunogenicity in the context of
nfection. There is evidence from recent studies that AR GP4-I is
usceptible to antibody-mediated selective pressure in vivo, and its
igh variability conﬁrms that aa changes in this region are generally
ell tolerated by the virus [33,53,55,60,61]. One might speculate
hat the high immunogenicity of this region is at the expense of the
mmunogenicity of other, more conserved neutralizing epitopes,
hich would offer the virus an evolutionary advantage. Although
t can feel contradictory that a decoy epitope is associated with pro-
ective immunity, a neutralizing epitope for which the emergence9 (2011) 4794– 4804
of  antibody-escape mutant viruses within the quasispecies popu-
lation is easily allowed, can perfectly act as decoy for neutralizing
epitopes in which aa changes are less frequently tolerated. For NA-
type PRRSV, it was suggested that GP5 contains a non-neutralizing
decoy epitope that compromises the immunogenicity of the neu-
tralizing epitope corresponding to AR GP5-I of LV [31]. The current
study however shows no evidence for either the presence of such
a decoy epitope in GP5 of LV or the susceptibility of AR GP5-I to
antibody-mediated neutralization. EU- and NA-type PRRSV proba-
bly evolved separately during a considerable amount of time, and
it is not unlikely that both genotypes developed different immune
evasion strategies [16].
Earlier studies, in particular the studies of de Lima et al. [44]
and Oleksiewicz et al. [38,40], have provided large maps of anti-
genic regions that are capable of inducing antibodies in infected
pigs. However, these authors did not investigate the neutraliz-
ing capacity of epitope-speciﬁc antibodies. The approach that was
used in the current study to characterize ARs, consisting of pep-
scan analysis with porcine antisera, followed by neutralization tests
with peptide-puriﬁed serum antibodies, was successfully used in
the past to characterize ARs in GP4, and allows the study of ARs
against which no mAbs are available [49]. Furthermore, the use of
primary cells, homologous virus that has not been adapted to cell
culture and antibodies from the natural host in neutralization tests
maximizes the in vivo relevance of the results. Although caution
is needed when relating in vitro virus neutralization with in vivo
protection, it seems reasonable to expect that neutralizing anti-
bodies as detected here can contribute to protective immunity in
pigs. The detection of antibodies speciﬁc for ARs GP3-I and GP4-I in
BAL ﬂuids of infected animals conﬁrms that neutralizing antibodies
are present at the major site of viral replication, where they may
contribute to viral clearance.
Considering the development of new generation PRRSV vaccines
that aim to induce virus-neutralizing antibodies, AR GP3-I in partic-
ular shows some interesting properties. Antibodies against this AR
in LV, but also against the corresponding region in the EU-type ﬁeld
isolates 07V063 and 08V204, are able to reduce viral infectivity, and
a large majority of pigs seem able to develop GP3-I-speciﬁc antibod-
ies upon infection. Further studies should address to what extent
the sensitivity of this AR to antibody-mediated neutralization is
conserved amongst a broader range of PRRSV strains.
Since different viruses induced antibodies against different pep-
tides within AR GP3-I, it is currently not clear how this AR can be
more generally deﬁned. Furthermore, it is not known to which
extent structural properties of the entire protein determine the
antigenic properties and immunogenicity of AR GP3-I. This infor-
mation will be essential for subunit vaccine development, and to be
able to determine antigenic cross-reactivity between virus strains
at the level of this epitope.
AR  GP3-I is genetically relatively well conserved, especially
compared to AR GP4-I [38,42,61,62]. However, it is not clear
to what extent this AR is well conserved because it fulﬁlls an
important function for the virus, or because no strong selective
pressure was  present on this region during PRRSV evolution. In
case variability in this sequence is functionally restricted, targeting
the antibody response towards this AR would be an appropri-
ate strategy, because the viability of virus mutants that escape
antibody-mediated neutralization at the level of this AR will be
largely compromised, and escape-mutant viruses will rarely sur-
vive. If the aa sequence of this region is however less essential for
the virus viability, targeting the immune response towards this AR
would enhance the selective pressure, and create a driving force
in the evolution of this particular region, similar to what happens
in AR GP4-I [33,53]. Hence, it should be thoroughly investigated to
what extent the virus can tolerate aa changes in certain ARs before
considering vaccine development. This can be done by cultivating
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he virus in vitro in the presence of epitope-speciﬁc neutralizing
ntibodies while monitoring the appearance of antibody-escape
utant viruses, as earlier described for the neutralizing epitope in
P4 [33]. More generally, a vaccine against a rapidly evolving RNA
irus that exists as a quasispecies population should always aim
o stimulate as many different protective immune mechanisms as
ossible to minimize the risk of emergence of virus variants that
scape the host’s immune system.
Many experimental vaccines based on one or more PRRSV enve-
ope proteins have been developed and tested with variable success
63]. Because GP5 is often considered the major target for PRRSV
rotective immunity, the main focus was put on this protein in sub-
nit vaccine development for a long time. It becomes however more
nd more clear that other envelope proteins also contain impor-
ant determinants of protective immunity, and it is encouraging
o notice that recent studies also consider the minor envelope pro-
eins for subunit vaccine development [38,45,64,65]. Some of these
tudies indicated the involvement of GP2 and GP3 in clinical and
irological protection, although it was not assessed to what extent
his protective effect could be attributed to stimulation of the GP2-
nd GP3-speciﬁc neutralizing antibody response [66–70].
The  current study aimed to characterize linear ARs in the entire
et of envelope proteins of LV, and new targets for both non-
eutralizing and neutralizing antibodies were identiﬁed. This work
rovides new insights into PRRSV antigenicity, and contributes to
nowledge on protective immunity and immune evasion strategies
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